{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:05:20Z","timestamp":1779361520609,"version":"3.51.4"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11095-025-03949-6","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:19:36Z","timestamp":1761581976000},"page":"1893-1916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spotlight on Clinical In-Use Parameters for Intravenous Infusion of Therapeutic Antibodies: A Systematic Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Puja","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2748-0026","authenticated-orcid":false,"given":"Haichen","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"3","key":"3949_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4161\/mabs.19931","volume":"4","author":"JM Reichert","year":"2012","unstructured":"Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4(3):413\u20135.","journal-title":"MAbs"},{"key":"3949_CR2","unstructured":"BioSpace. Bispecific antibodies market size projected to reach USD 484.88 bn by 2034. 2025. Available from: https:\/\/www.biospace.com\/press-releases\/bispecific-antibodies-market-size-projected-to-reach-usd-484-88-bn-by-2034. Accessed\u00a009 July 2025."},{"key":"3949_CR3","unstructured":"Society TA. Antibody therapeutics approved or in regulatory review in the EU or US. 2024. Available from: https:\/\/www.antibodysociety.org\/resources\/approved-antibodies\/. Accessed\u00a014 July 2025."},{"issue":"1","key":"3949_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2443538","volume":"17","author":"S Crescioli","year":"2025","unstructured":"Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538.","journal-title":"MAbs"},{"issue":"1","key":"3949_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450","volume":"16","author":"S Crescioli","year":"2024","unstructured":"Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs. 2024;16(1):2297450.","journal-title":"MAbs"},{"issue":"3","key":"3949_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","volume":"151","author":"RS D\u2019Amico","year":"2021","unstructured":"D\u2019Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. Convection-enhanced drug delivery for glioblastoma: a review. J Neurooncol. 2021;151(3):415\u201327.","journal-title":"J Neurooncol"},{"key":"3949_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/antib11030056","author":"A Pitiot","year":"2022","unstructured":"Pitiot A, Heuz\u00e9-Vourc\u2019h N, S\u00e9cher T. Alternative routes of administration for therapeutic antibodies-state of the art. Antibodies. 2022. https:\/\/doi.org\/10.3390\/antib11030056.","journal-title":"Antibodies"},{"issue":"8","key":"3949_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1208\/s12249-023-02661-1","volume":"24","author":"M Rahamathulla","year":"2023","unstructured":"Rahamathulla M, Murugesan S, Gowda DV, Alamri AH, Ahmed MM, Osmani RAM, et al. The use of nanoneedles in drug delivery: an overview of recent trends and applications. AAPS PharmSciTech. 2023;24(8):216.","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"3949_CR9","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1016\/j.xphs.2023.07.026","volume":"112","author":"BD Mason","year":"2023","unstructured":"Mason BD, Lowe K, Dong J, Salamat-Miller N. A practical tool for risk-based in-use compatibility assessments. J Pharm Sci. 2023;112(11):2938\u201346.","journal-title":"J Pharm Sci"},{"issue":"9","key":"3949_CR10","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.xphs.2023.05.002","volume":"112","author":"M Bl\u00fcmel","year":"2023","unstructured":"Bl\u00fcmel M, Liu J, de Jong I, Weiser S, Fast J, Litowski J, et al. Current industry best practice on in-use stability and compatibility studies for biological products. J Pharm Sci. 2023;112(9):2332\u201346.","journal-title":"J Pharm Sci"},{"issue":"4","key":"3949_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.xphs.2021.09.043","volume":"111","author":"DE Kamen","year":"2022","unstructured":"Kamen DE, Crotts G, Narasimhan C, Hu Q, Bhargava AC, Muthurania K, et al. An intercompany perspective on compatibility and in-use stability studies to enable administration of biopharmaceutical drug products. J Pharm Sci. 2022;111(4):1092\u2013103.","journal-title":"J Pharm Sci"},{"key":"3949_CR12","unstructured":"Regeneron. Veopoz. In: Prescribing information. Tarrytown, NY 10591. 2024. Available from: https:\/\/www.regeneron.com\/downloads\/veopoz_fpi.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR13","unstructured":"Genentech. Columvi. In: Prescribing information. South San Francisco, CA 94080. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR14","unstructured":"Company ELa. Omvoh. In: Prescribing information. Indianapolis, IN 46285. 2024. Available from: https:\/\/uspl.lilly.com\/omvoh\/omvoh.html#pi. Accessed 12 Aug 2024."},{"key":"3949_CR15","unstructured":"Eisai. Leqembi. In: Prescribing information. Nutley, NJ 07110. 2023. Available from: https:\/\/www.leqembi.com\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR16","unstructured":"Biosciences C. LoqtorzI. In: Prescribing information. Redwood City, CA 94065. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761240s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR17","unstructured":"Corporation I. Zynyz. In: Prescribing information. Wilmington, DE 19803. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761334s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR18","unstructured":"Bio P. Tzield. In: Prescribing information. Red Bank, NJ 07701. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761183s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR19","unstructured":"Therapeutics T. Briumvi. In: Prescribing information. Morrisville, NC 27560. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761238s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR20","unstructured":"ImmunoGen. Elahere. In: Prescribing information. Waltham, MA 02451. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR21","unstructured":"AstraZeneca. Imjudo. In: Prescribing information. Wilmington, DE 19850. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761270s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR22","unstructured":"Pharmaceuticals BI. Spevigo. In: Prescribing information. Ridgefield, CT 06877. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR23","unstructured":"Genentech. Lunsumio. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/lunsumio_prescribing.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR24","unstructured":"Company B-MS. Opdualag. In: Prescribing information. Princeton, NJ 08543. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761234s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR25","unstructured":"Immunocore. Kimmtrak. In: Prescribing information. United Kingdom, OX144RY. 2022. Available from: https:\/\/d1io3yog0oux5.cloudfront.net\/_f594b2acb40fb5e6ac99c2f7cf8cc3f4\/immunocore\/files\/documents\/Approved_USPI_11_20_22_for_commercial_printing_and_website.pdf. Accessed 12 Aug 2024.\u00a0"},{"key":"3949_CR26","unstructured":"Sanofi. Enjaymo. In: Prescribing information. Waltham, MA 02451. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761164s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR27","unstructured":"GlaxoSmithKline. Sotrovimab. In: Prescribing information. Philadelphia, PA 19104. 2023. Available from: https:\/\/www.fda.gov\/media\/149534\/download. Accessed 12 Aug 2024."},{"key":"3949_CR28","unstructured":"Healthcare C. Regkirona. In: Prescribing information. Sydney NSW 2000. 2021. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-regdanvimab-211206-pi_0.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR29","unstructured":"Pharma R. Ronapreve. In: Prescribing information. Basel, Switzerland. 2023. Available from: https:\/\/www.swissmedicinfo.ch\/ShowText.aspx?textType=FI&lang=EN&authNr=68329. Accessed 12 Aug 2024."},{"key":"3949_CR30","unstructured":"Seagen. Tivdak. In: Prescribing information. Bothell, WA 98021. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761208Orig1s000lbledt.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR31","unstructured":"AstraZeneca. Saphnelo. In: Prescribing information. Wilmington, DE 19850.\u00a0 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR32","unstructured":"Biogen. Aduhelm. In: Prescribing information. Cambridge, MA 02142. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR33","unstructured":"Novartis. Cosentyx. In: Prescribing information. East Hanover, New Jersey 07936. 2023. Available from: https:\/\/www.novartis.com\/usen\/sites\/novartis_us\/files\/cosentyx.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR34","unstructured":"Biotech J. Rybrevant. In: Prescribing information. Horsham, PA 19044. 2024. Available from: https:\/\/www.janssenlabels.com\/package-insert\/productmonograph\/prescribing-information\/RYBREVANT-pi.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR35","unstructured":"Therapeutics A. Zynlonta. In: Prescribing information. Murray Hill, New Jersey 07974. 2022. Available from: https:\/\/www.adctherapeutics.com\/wpcontent\/uploads\/2023\/10\/ZYNLONTA-PI_October-2022_LOCKED.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR36","unstructured":"GlaxoSmithKline. Jemperli. In: Prescribing information. Philadelphia, PA 19104. 2024.https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Jemperli\/pdf\/JEMPERLI-PI-MG.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR37","unstructured":"Regeneron. Evkeeza. In: Prescribing information. Tarrytown, NY 10591. 2023. Available from: https:\/\/www.regeneron.com\/downloads\/evkeeza_pi.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR38","unstructured":"Therapeutics R. Ebanga. In: Prescribing information. Miami, FL 33133. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761172s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR39","unstructured":"Amgen. Riabni. In: Prescribing information. Thousand Oaks, CA 91320. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761140s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR40","unstructured":"MacroGenics. Margenza. In: Prescribing information. Rockville, MD 20850. 2023. Available from: https:\/\/www.margenza.com\/pdf\/prescribing-information.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR41","unstructured":"Y-mAbs. Danyelza. In: Prescribing information. New York, NY 10169. 2024.\u00a0Available from: https:\/\/labeling.ymabs.com\/danyelza. Accessed 12 Aug 2024."},{"key":"3949_CR42","unstructured":"Regeneron. Inmazeb. In: Prescribing information. Tarrytown, NY 10591. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761169s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR43","unstructured":"GlaxoSmithKline. Blenrep. In: Prescribing information. Research Triangle Park, NC 27709. 2022. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF. Accessed 12 Aug 2024."},{"key":"3949_CR44","unstructured":"Morphosys. Monjuvi. In: Prescribing information. Boston, MA 02210. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761163s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR45","unstructured":"Bio V. UPLIZNA. In: Prescribing information. Gaithersburg, MD 20878. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761142s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR46","unstructured":"Immunomedics. Trodelvy. In: Prescribing Information. Morris Plains, NJ 07950. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR47","unstructured":"Sanofi-Aventis. Sarclisa. In: Prescribing information. Bridgewater, NJ 08807. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761113s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR48","unstructured":"BioPharmaceuticals LS. Vyepti. In: Prescribing information. Bothell, WA 98011. 2022. Available from: https:\/\/www.lundbeck.com\/content\/dam\/lundbeckcom\/americas\/united-states\/products\/neurology\/vyepti_pi_us_en.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR49","unstructured":"Therapeutics H. Tepezza. In: Prescribing information. Deerfield, IL 60015. 2023. Available from: https:\/\/www.hzndocs.com\/TEPEZZA-Prescribing-Information.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR50","unstructured":"Sankyo D. Enhertu. In: Prescribing information. Basking Ridge, NJ 07920. 2024. Available from: https:\/\/daiichisankyo.us\/prescribing-informationportlet\/getPIContent?productName=Enhertu&inline=true. Accessed 12 Aug 2024."},{"key":"3949_CR51","unstructured":"Pharma A. Padcev. In: Prescribing information. Northbrook, Illinois 60062. 2023. Available from: https:\/\/astellas.us\/docs\/padcev_label.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR52","unstructured":"Novartis. Adakveo. In: Prescribing information. East Hanover, New Jersey 07936. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR53","unstructured":"Genentech. Polivy. In: Prescribing information. South San Francisco, CA 94080. 2023. Available from: https:\/\/www.gene.com\/download\/pdf\/polivy_prescribing.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR54","unstructured":"AbbVie. Skyrizi. In: Prescribing information. North Chicago, IL 60064. 2024.\u00a0Available from: https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR55","unstructured":"Pharmaceuticals A. Ultomiris. In: Prescribing information. Boston, MA 02210. 2024. Available from: https:\/\/alexion.com\/Documents\/Ultomiris_USPI.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR56","unstructured":"Sobi. Gamifant. In: Prescribing information. Waltham, MA 02451. 2024. Available from: https:\/\/gamifant.com\/pdf\/Full-Prescribing-Information.pdf?_ga=2.51195948.427838726.1703176959-426950346.1703176959&_gac=1.142346758.1703176959.EAIaIQobChMIkzJy_yggwMVUkhHAR3L3QqGEAAYASAAEgKosPD_BwE. Accessed 12 Aug 2024."},{"key":"3949_CR57","unstructured":"Regeneron. LIBTAYO. In: Prescribing information. Tarrytown, NY 10591. 2024. Available from: https:\/\/www.regeneron.com\/downloads\/libtayo_fpi.pd. Accessed 12 Aug 2024."},{"key":"3949_CR58","unstructured":"Kirin K. Poteligeo. In: Prescribing information. Bedminster, NJ 07921. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761051s000lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR59","unstructured":"Biologics T. Trogarzo. In: Prescribing information. Irvine, California 92614. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761065lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR60","unstructured":"Pfizer. Mylotarg. In: Prescribing information. Philadelphia, PA 19101. 2021. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=9548. Accessed 12 Aug 2024."},{"key":"3949_CR61","unstructured":"Pfizer. Besponsa. In: Prescribing information. Philadelphia, PA 19101. 2024. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=9503. Accessed 12 Aug 2024."},{"key":"3949_CR62","unstructured":"Genentech. Rituxan. In: Prescribing information. South San Francisco, CA 94080. 2021. Available from: https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR63","unstructured":"AstraZeneca. Imfinzi. In: Prescribing information. Wilmington, DE 19850. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761069s033lbl.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR64","unstructured":"Genentech. Ocrevus. In: Prescribing information. South San Francisco, CA 94080. 2024. Available from: https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR65","unstructured":"Serono E. Bavencio. In: Prescribing information. Rockland, MA 02370. 2024. Available from: https:\/\/www.emdserono.com\/us-en\/pi\/bavencio-pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR66","unstructured":"Merck. Zinplava. In: Prescribing information. Rahway, NJ 07065. 2023. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zinplava\/zinplava_pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR67","unstructured":"Company ELa. Lartruvo. In: Prescribing information. Indianapolis, IN 46285. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761038lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR68","unstructured":"Genentech. Tecentriq. In: Prescribing information. South San Francisco, CA 94080. 2024. Available from: https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR69","unstructured":"Teva. Cinqair. In: Prescribing information. West Chester, PA 19380. 2020. Available from: https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR70","unstructured":"Therapeutics E. Anthim. In: Prescribing information. Pine Brook, NJ 07058. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125509lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR71","unstructured":"Squibb BM. Empliciti. In: Prescribing information. Princeton, NJ 08543. 2022.\u00a0Available from: https:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf. Accessed 13\u00a0Aug 2024."},{"key":"3949_CR72","unstructured":"Company ELa. Portrazza. In: Prescribing information. Indianapolis, IN 46285. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125547s000lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR73","unstructured":"Biotech J. Darzalex. In: Prescribing information. Horsham, PA 19044. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761036s041lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR74","unstructured":"Pharmaceuticals BI. Praxbind. In: Prescribing information. Ridgefield, CT 06877. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/761025lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR75","unstructured":"Therapeutics U. Unituxin. In: Prescribing information. Silver Spring, MD 20910. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125516s000lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR76","unstructured":"Amgen. Blincyto. In: Prescribing information. Thousand Oaks, CA 91320. 2024. Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/piamgen-com\/blincyto\/blincyto_pi_hcp_english.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR77","unstructured":"Squibb BM. Opdivo. In: Prescribing information. Princeton, NJ 08543. 2024. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR78","unstructured":"Corporation G. Lemtrada. In: Prescribing information. Cambridge, MA 02141. 2024. Available from: https:\/\/products.sanofi.us\/lemtrada\/lemtrada.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR79","unstructured":"Merck. KEYTRUDA. In: Prescribing information. Rahway, NJ 07065. 2024. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR80","unstructured":"Pharmaceuticals T. Entyvio. In: Prescribing information. Lexington, MA 02421. 2024. Available from: https:\/\/content.takeda.com\/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1. Accessed 13 Aug 2024."},{"key":"3949_CR81","unstructured":"Pharma E. Sylvant. In: Prescribing information. Hemel Hempstead, Hertfordshire, U.K. 2019. Available from: https:\/\/sylvant.com\/wpcontent\/themes\/sylvant\/assets\/docs\/sylvant-prescribing-info.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR82","unstructured":"Company ELa. Cyramza. In: Prescribing information. Indianapolis, IN 46285. 2022. Available from: https:\/\/uspl.lilly.com\/cyramza\/cyramza.html#pi. Accessed 13 Aug 2024."},{"key":"3949_CR83","unstructured":"Genentech. Gazyva. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/gazyva_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR84","unstructured":"Biotech J. Simponi aria. In: Prescribing information. Horsham, PA 19044. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125433s032lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR85","unstructured":"Genentech. Kadcyla. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/kadcyla_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR86","unstructured":"Sciences HG. Raxibacumab. In: Prescribing information. Rockville, MD 20850. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125349s000lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR87","unstructured":"Genentech. Perjeta. In: Prescribing Information. South San Francisco, CA 94080. 2021. Available from: https:\/\/www.gene.com\/download\/pdf\/perjeta_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR88","unstructured":"Seagen. Adcetris. In: Prescribing information. Bothell, WA 98021. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125388s106lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR89","unstructured":"Squibb BM. Yervoy. In: Prescribing information. Princeton, NJ 08543. 2023. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR90","unstructured":"GlaxoSmithKline. Benlysta. In: Prescribing information. Philadelphia, PA 19104. 2024. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF. Accessed 13 Aug 2024."},{"key":"3949_CR91","unstructured":"Genentech. Actemra. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR92","unstructured":"Novartis. Arzerra. In: Prescribing information. East Hanover, New Jersey 07936. 2016. Available from: https:\/\/www.novartis.com\/usen\/sites\/novartis_us\/files\/arzerra.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR93","unstructured":"Biotech J. Stelara. In: Prescribing information. Horsham, PA 19044. 2024. Available from: https:\/\/www.janssenlabels.com\/package-insert\/productmonograph\/prescribing-information\/STELARA-pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR94","unstructured":"Amgen. VectibiX. In: Prescribing information. Thousand Oaks, CA 91320. 2021. Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/piamgen-com\/Vectibix\/vectibix_pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR95","unstructured":"Squibb BM. Orencia. In: Prescribing information. Princeton, NJ 08543. 2024. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR96","unstructured":"Biogen. Tysabri. In: Prescribing information. Cambridge, MA 02142. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125104s0576lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR97","unstructured":"Genentech. Avastin. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR98","unstructured":"Company ELa. Erbitux. In: Prescribing information. Indianapolis, IN 46285. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125084s273lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR99","unstructured":"GlaxoSmithKline. Bexxar. In: Prescribing Information. Research Triangle Park, NC 27709. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125011s102lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR100","unstructured":"Pharmaceuticals S. Zevalin. In: Prescribing information. Irvine, CA 92618. 2009. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125019s0156.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR101","unstructured":"Corporation G. Campath. In: Prescribing information. Cambridge, MA 02142. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103948s5171lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR102","unstructured":"Genentech. Herceptin. In: Prescribing information. South San Francisco, CA 94080. 2010. Avaialble from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR103","unstructured":"Biotech J. Remicade. In: Prescribing information. Horsham, PA 19044. 2021. Available from: https:\/\/www.janssenlabels.com\/package-insert\/productmonograph\/prescribing-information\/REMICADE-pi.pdf. Accessed 13 Aug 2024."},{"key":"3949_CR104","unstructured":"AstraZeneca. LUMOXITI. In: Prescribing information. Horsham, PA 19044. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761104s000lbl.pdf. Accessed 13 Aug 2024."},{"issue":"1","key":"3949_CR105","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1993768","volume":"13","author":"Y Tang","year":"2021","unstructured":"Tang Y, Cain P, Anguiano V, Shih JJ, Chai Q, Feng Y. Impact of IgG subclass on molecular properties of monoclonal antibodies. MAbs. 2021;13(1):1993768.","journal-title":"MAbs"},{"issue":"9","key":"3949_CR106","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/pro.2118","volume":"21","author":"JT Heads","year":"2012","unstructured":"Heads JT, Adams R, D\u2019Hooghe LE, Page MJ, Humphreys DP, Popplewell AG, et al. Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci. 2012;21(9):1315\u201322.","journal-title":"Protein Sci"},{"issue":"6","key":"3949_CR107","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2059310","volume":"18","author":"S Basu","year":"2022","unstructured":"Basu S, Rustagi R. Multi-dose vials versus single-dose vials for vaccination: perspectives from lower-middle income countries. Hum Vaccin Immunother. 2022;18(6):2059310.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3949_CR108","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bjid.2012.09.005","volume":"17","author":"S Baniasadi","year":"2013","unstructured":"Baniasadi S, Dorudinia A, Mobarhan M, Karimi Gamishan M, Fahimi F. Microbial contamination of single- and multiple-dose vials after opening in a pulmonary teaching hospital. Braz J Infect Dis. 2013;17(1):69\u201373.","journal-title":"Braz J Infect Dis"},{"issue":"32","key":"3949_CR109","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1016\/j.vaccine.2010.05.048","volume":"28","author":"BY Lee","year":"2010","unstructured":"Lee BY, Norman BA, Assi TM, Chen SI, Bailey RR, Rajgopal J, et al. Single versus multi-dose vaccine vials: an economic computational model. Vaccine. 2010;28(32):5292\u2013300.","journal-title":"Vaccine"},{"key":"3949_CR110","doi-asserted-by":"crossref","unstructured":"Kommineni N, Butreddy A, Sainaga Jyothi VGS, Angsantikul P. Freeze-drying for the preservation of immunoengineering products. iScience. 2022;25(10):105127.","DOI":"10.1016\/j.isci.2022.105127"},{"key":"3949_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.717689","volume":"11","author":"KT Schneider","year":"2021","unstructured":"Schneider KT, Kirmann T, Wenzel EV, Grosch JH, Polten S, Meier D, et al. Shelf-life extension of Fc-fused single chain fragment variable antibodies by lyophilization. Front Cell Infect Microbiol. 2021;11:717689.","journal-title":"Front Cell Infect Microbiol"},{"key":"3949_CR112","first-page":"31","volume":"13","author":"A Bhambhani","year":"2010","unstructured":"Bhambhani A, Blue JT. Lyophilization strategies for development of a high-concentration monoclonal antibody formulation: benefits and pitfalls. Am Pharm Rev. 2010;13:31\u20138.","journal-title":"Am Pharm Rev"},{"issue":"7","key":"3949_CR113","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.xphs.2022.03.002","volume":"111","author":"WJ Fang","year":"2022","unstructured":"Fang WJ, Ingle RG, Liu JW, Ge XZ, Wang H. Freeze-dried monoclonal antibody formulations are unexpectedly more prone to degradation than liquid formulations under shaking stress. J Pharm Sci. 2022;111(7):2134\u20138.","journal-title":"J Pharm Sci"},{"key":"3949_CR114","unstructured":"Australian product information \u2013 trodelvy. In. Australian Public Assessment Reports. 2021. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-sacituzumab-govitecan-220329-pi.pdf. Accessed 19 Sept 2024."},{"key":"3949_CR115","unstructured":"Agency EM. Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use. In: (CHMP) CfHMP, editor. 30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom: European Medicines Agency. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-andanswers-benzyl-alcohol-used-excipient-medicinal-products-human-use_en.pdf. Accessed 12 Aug 2024."},{"key":"3949_CR116","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ddtec.2020.08.005","volume":"37","author":"\u00c9 Koll\u00e1r","year":"2020","unstructured":"Koll\u00e1r \u00c9, Bal\u00e1zs B, Tari T, Sir\u00f3 I. Development challenges of high concentration monoclonal antibody formulations. Drug Discovery Today: Technologies. 2020;37:31\u201340.","journal-title":"Drug Discovery Today: Technologies"},{"issue":"1","key":"3949_CR117","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2211185","volume":"15","author":"J Zarzar","year":"2023","unstructured":"Zarzar J, Khan T, Bhagawati M, Weiche B, Sydow-Andersen J, Sreedhara A. High concentration formulation developability approaches and considerations. MAbs. 2023;15(1):2211185.","journal-title":"MAbs"},{"issue":"5","key":"3949_CR118","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/bit.22336","volume":"103","author":"JS Bee","year":"2009","unstructured":"Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R, et al. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng. 2009;103(5):936\u201343.","journal-title":"Biotechnol Bioeng"},{"issue":"8","key":"3949_CR119","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11095-025-03888-2","volume":"42","author":"G Hu","year":"2025","unstructured":"Hu G, Li C, Wang K, Su Y, Forrest W, Givand J, et al. Investigating zinc migration from rigid needle shield to drug formulation in needle tip of pre-filled syringe. Pharm Res. 2025;42(8):1385\u201396.","journal-title":"Pharm Res"},{"key":"3949_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.04.009","author":"VP Griffin","year":"2024","unstructured":"Griffin VP, Pace S, Ogunyankin MO, Holstein M, Hung J, Dhar P. Understanding the impact of combined hydrodynamic shear and interfacial dilatational stress, on interface-mediated particle formation for monoclonal antibody formulations. J Pharm Sci. 2024. https:\/\/doi.org\/10.1016\/j.xphs.2024.04.009.","journal-title":"J Pharm Sci"},{"key":"3949_CR121","unstructured":"Sterile hypodermic syringes for single use. In: ISO 7886-1. 2017. Available from: https:\/\/www.iso.org\/standard\/64790.html. Accessed 16 Sept 2024."},{"issue":"13","key":"3949_CR122","first-page":"5604","volume":"49","author":"CR Sanchez","year":"2008","unstructured":"Sanchez CR, Shah SN, Weinberg DV. Accuracy and precision of intraocular injections using tuberculin vs. high precision syringes. Invest Ophthalmol Vis Sci. 2008;49(13):5604\u20135604.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"3949_CR123","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.oret.2023.06.003","volume":"7","author":"LLM Agra","year":"2023","unstructured":"Agra LLM, Sverstad A, Chagas TA, Ara\u00fajo RH, Oliveira LG, Kristianslund O, et al. Accuracy, precision, and residual volume of commonly used syringes for intravitreal injections and the impact on intraocular pressure. Ophthalmol Retina. 2023;7(10):892\u2013900.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"3949_CR124","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0018578719873869","volume":"56","author":"MA Jordan","year":"2021","unstructured":"Jordan MA, Choksi D, Lombard K, Patton LR. Development of guidelines for accurate measurement of small volume parenteral products using syringes. Hosp Pharm. 2021;56(3):165\u201371.","journal-title":"Hosp Pharm"},{"issue":"5","key":"3949_CR125","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/NCC.0b013e318208f2ca","volume":"34","author":"Z Stamataki","year":"2011","unstructured":"Stamataki Z, Burden S, Molassiotis A. Weight changes in oncology patients during the first year after diagnosis: a qualitative investigation of the patients\u2019 experiences. Cancer Nurs. 2011;34(5):401\u20139.","journal-title":"Cancer Nurs"},{"issue":"9","key":"3949_CR126","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2001.19.9.2381","volume":"19","author":"W Demark-Wahnefried","year":"2001","unstructured":"Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001;19(9):2381\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3949_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002349","volume":"9","author":"M Ahmed","year":"2021","unstructured":"Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, et al. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2021;9(6):e002349.","journal-title":"J Immunother Cancer"},{"issue":"16_suppl","key":"3949_CR128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13573","volume":"42","author":"J Fernandez","year":"2024","unstructured":"Fernandez J, Indurlal P, Garey JS, Wilfong LS. Financial impact of fixed-dose versus weight-based dosing approaches for pembrolizumab and nivolumab in the Oncology Care Model for the US Oncology Network (the Network). J Clin Oncol. 2024;42(16_suppl):e13573\u2013e13573.","journal-title":"J Clin Oncol"},{"key":"3949_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040730","author":"S Monirul","year":"2020","unstructured":"Monirul S, Rigal M, Chouahnia K, Le Jouan M, Apparuit M, Paix A, et al. Budget impact analysis of fixed dose versus weight-based dosing regimen of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer. Vaccines. 2020. https:\/\/doi.org\/10.3390\/vaccines8040730.","journal-title":"Vaccines"},{"key":"3949_CR130","unstructured":"Chaitesipaseut L, Shah N, Truong T-G, Niu F, Shin P, Sharma K, Smith J, Hui RL. Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer. J Oncol Pharm Pract;0(0):10781552231212926."},{"issue":"3","key":"3949_CR131","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1310\/hpj4903-221","volume":"49","author":"MR Cohen","year":"2014","unstructured":"Cohen MR, Smetzer JL. Understanding and managing intravenous container overfill; potential dose confusion. Hosp Pharm. 2014;49(3):221\u20136.","journal-title":"Hosp Pharm"},{"key":"3949_CR132","unstructured":"IV push medication and doses. In: UConn JDH IV medication administration guidelines and updates. Available from: https:\/\/health.uconn.edu\/policies\/wpcontent\/uploads\/sites\/28\/2023\/08\/IV-Medication-Guidelines.pdf. Accessed 16 Sept 2024."},{"key":"3949_CR133","unstructured":"SOP Expired Medical Materials. In: Oakland University SOP. Available from: https:\/\/www.oakland.edu\/Assets\/upload\/docs\/Research\/SOP_Use_of_Exp_Med_Materials.pdf. Accessed 16 Sept 2024."},{"key":"3949_CR134","doi-asserted-by":"crossref","unstructured":"Cohen MR. Medication errors. 2nd ed. American Pharmacists Association. 2007. p. 142.","DOI":"10.21019\/9781582120928"},{"key":"3949_CR135","unstructured":"Nomination from Pentec Health. In: Bulk drug substance nomination. 2019. Available from: https:\/\/www.regulation.gov\/document\/FDA-2015-N-3469-0267. Accessed 16 Sept 2024."},{"key":"3949_CR136","unstructured":"UConn health intravenous solution bag overfill. 2016. Available from: https:\/\/health.uconn.edu\/pharmacy\/wp-content\/uploads\/sites\/60\/2016\/03\/Intravenous-Bag-Overfill.pdf. Accessed 12 Sept 2024."},{"key":"3949_CR137","unstructured":"Institute for Safe Medication Practices Canada. Managing overfill during preparation and delivery of intravenous medications. 2013. Available from: https:\/\/ismpcanada.ca\/wp-content\/uploads\/ISMPCSB2013-07_ManagingOverfillIntravenousMedications.pdf. Accessed 16 Sept 2024."},{"issue":"4","key":"3949_CR138","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.xphs.2020.10.036","volume":"110","author":"A Kannan","year":"2021","unstructured":"Kannan A, Shieh IC, Hristov P, Fuller GG. In-use interfacial stability of monoclonal antibody formulations diluted in saline i.v. bags. J Pharm Sci. 2021;110(4):1687\u201392.","journal-title":"J Pharm Sci"},{"issue":"8","key":"3949_CR139","first-page":"1739","volume":"42","author":"DP Wermeling","year":"1985","unstructured":"Wermeling DP, Rapp RP, DeLuca PP, Piecoro JJ Jr. Osmolality of small-volume intravenous admixtures. Am J Hosp Pharm. 1985;42(8):1739\u201344.","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"3949_CR140","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40268-020-00329-w","volume":"21","author":"S Manrique-Rodr\u00edguez","year":"2021","unstructured":"Manrique-Rodr\u00edguez S, Heras-Hidalgo I, Pernia-L\u00f3pez MS, Herranz-Alonso A, Del R\u00edo Pisabarro MC, Su\u00e1rez-Mier MB, et al. Standardization and chemical characterization of intravenous therapy in adult patients: a step further in medication safety. Drugs R D. 2021;21(1):39\u201364.","journal-title":"Drugs R D"},{"key":"3949_CR141","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jchromb.2018.12.021","volume":"1105","author":"B Demirdirek","year":"2019","unstructured":"Demirdirek B, Lan W, Qiu D, Ding W, Iyer LK, Bolgar MS, et al. Comparison of imaged capillary isoelectric focusing and cation exchange chromatography for monitoring dextrose-mediated glycation of monoclonal antibodies in infusion solutions. J Chromatogr B. 2019;1105:156\u201363.","journal-title":"J Chromatogr B"},{"issue":"1","key":"3949_CR142","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejpb.2008.04.021","volume":"70","author":"S Fischer","year":"2008","unstructured":"Fischer S, Hoernschemeyer J, Mahler H-C. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm. 2008;70(1):42\u201350.","journal-title":"Eur J Pharm Biopharm"},{"key":"3949_CR143","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jbiotec.2013.11.007","volume":"170","author":"B Liu","year":"2014","unstructured":"Liu B, Spearman M, Doering J, Lattov\u00e1 E, Perreault H, Butler M. The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody. J Biotechnol. 2014;170:17\u201327.","journal-title":"J Biotechnol"},{"key":"3949_CR144","doi-asserted-by":"crossref","unstructured":"Guynn JB Jr, Poretz DM, Duma RJ. Growth of various bacteria in a variety of intravenous fluids. Am J Hosp Pharm. 1973;30(4):321\u20135.","DOI":"10.1093\/ajhp\/30.4.321"},{"issue":"1","key":"3949_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00489-6","volume":"8","author":"Y Aoyagi","year":"2020","unstructured":"Aoyagi Y, Yoshida T, Uchino S, Takinami M, Uezono S. Saline versus 5% dextrose in water as a drug diluent for critically ill patients: a retrospective cohort study. J Intensive Care. 2020;8(1):69.","journal-title":"J Intensive Care"},{"issue":"2","key":"3949_CR146","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cam4.3666","volume":"10","author":"A Jo","year":"2021","unstructured":"Jo A, Scarton L, O\u2019Neal LJ, Larson S, Schafer N, George TJ, et al. New onset of type 2 diabetes as a complication after cancer diagnosis: a systematic review. Cancer Med. 2021;10(2):439\u201346.","journal-title":"Cancer Med"},{"key":"3949_CR147","unstructured":"Demarco C. Diabetes as a side effect of cancer treatment: 8 things to know. 2021. Available from: https:\/\/www.mdanderson.org\/cancerwise\/diabetes-as-a-side-effect-ofcancer-treatment--8-things-to-know.h00-159464001.html. Accessed 12 Sept 2024."},{"issue":"3","key":"3949_CR148","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1213\/01.ANE.0000148617.98716.EB","volume":"100","author":"SC Minogue","year":"2005","unstructured":"Minogue SC, Sun DA. Bacteriostatic saline containing benzyl alcohol decreases the pain associated with the injection of propofol. Anesth Analg. 2005;100(3):683\u20136.","journal-title":"Anesth Analg"},{"issue":"3","key":"3949_CR149","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.21873\/anticanres.14062","volume":"40","author":"MD Rombouts","year":"2020","unstructured":"Rombouts MD, Swart EL, Van Den Eertwegh AJM, Crul M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 2020;40(3):1201\u201318.","journal-title":"Anticancer Res"},{"issue":"3","key":"3949_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922","volume":"9","author":"A Barroso","year":"2024","unstructured":"Barroso A, Estevinho F, Hespanhol V, Teixeira E, Ramalho-Carvalho J, Ara\u00fajo A. Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open. 2024;9(3):102922.","journal-title":"ESMO Open"},{"issue":"3","key":"3949_CR151","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11095-025-03841-3","volume":"42","author":"G Shi","year":"2025","unstructured":"Shi G, Shih H, Parker J, Patel H, Sirkar R, Sree V, et al. Clinical evaluation of the temperature dependence of subcutaneous injection experience in healthy volunteers. Pharm Res. 2025;42(3):475\u201384.","journal-title":"Pharm Res"},{"issue":"5","key":"3949_CR152","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-021-03047-3","volume":"38","author":"GH Shi","year":"2021","unstructured":"Shi GH, Pisupati K, Parker JG, Corvari VJ, Payne CD, Xu W, et al. Subcutaneous injection site pain of formulation matrices. Pharm Res. 2021;38(5):779\u201393.","journal-title":"Pharm Res"},{"issue":"7","key":"3949_CR153","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JOP.18.00143","volume":"14","author":"AK Nooka","year":"2018","unstructured":"Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, et al. Managing infusion reactions to new monoclonal antibodies in multiple myeloma: Daratumumab and elotuzumab. J Oncol Pract. 2018;14(7):414\u201322.","journal-title":"J Oncol Pract"},{"issue":"7","key":"3949_CR154","first-page":"5627","volume":"30","author":"S Dubinsky","year":"2022","unstructured":"Dubinsky S, Patel D, Wang X, Srikanthan A, Ng TL, Tsang C. Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis. Support Care Cancer. 2022;30(7):5627\u201344.","journal-title":"Support Care Cancer"},{"key":"3949_CR155","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/TCRM.S204909","volume":"15","author":"MC C\u00e1ceres","year":"2019","unstructured":"C\u00e1ceres MC, Guerrero-Mart\u00edn J, P\u00e9rez-Civantos D, Palomo-L\u00f3pez P, Delgado-Mingorance JI, Dur\u00e1n-G\u00f3mez N. The importance of early identification of infusion-related reactions to monoclonal antibodies. Ther Clin Risk Manag. 2019;15:965\u201377.","journal-title":"Ther Clin Risk Manag"},{"key":"3949_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5110093","author":"CJ McCarthy","year":"2016","unstructured":"McCarthy CJ, Behravesh S, Naidu SG, Oklu R. Air embolism: practical tips for prevention and treatment. J Clin Med. 2016. https:\/\/doi.org\/10.3390\/jcm5110093.","journal-title":"J Clin Med"},{"issue":"3","key":"3949_CR157","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa061","volume":"2","author":"B Bolla","year":"2020","unstructured":"Bolla B, Buxani Y, Wong R, Jones L, Dube M. Understanding IV antimicrobial drug losses: the importance of flushing infusion administration sets. JAC-Antimicrobial Resistance. 2020;2(3):dlaa061.","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"6","key":"3949_CR158","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/jps.20812","volume":"96","author":"JD Colandene","year":"2007","unstructured":"Colandene JD, Maldonado LM, Creagh AT, Vrettos JS, Goad KG, Spitznagel TM. Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent. J Pharm Sci. 2007;96(6):1598\u2013608.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3949_CR159","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/10781552231175820","volume":"30","author":"MA Marchal","year":"2024","unstructured":"Marchal MA, Robert M, Pesqu\u00e9 R, Jourdan N, Sessink P, Madelaine I, et al. Residual chemotherapy drugs after flushing infusion lines. J Oncol Pharm Pract. 2024;30(2):278\u201385.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"3949_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55113-x","volume":"9","author":"N Tokhadze","year":"2019","unstructured":"Tokhadze N, Chennell P, Bernard L, Lambert C, Pereira B, Mailhot-Jensen B, et al. Impact of alternative materials to plasticized PVC infusion tubings on drug sorption and plasticizer release. Sci Rep. 2019;9(1):18917.","journal-title":"Sci Rep"},{"issue":"20","key":"3949_CR161","doi-asserted-by":"publisher","first-page":"24858","DOI":"10.1021\/acsami.3c02354","volume":"15","author":"SS Jagarlapudi","year":"2023","unstructured":"Jagarlapudi SS, Cross HS, Das T, Goddard WA 3rd. Thermomechanical properties of nontoxic plasticizers for polyvinyl chloride predicted from molecular dynamics simulations. ACS Appl Mater Interfaces. 2023;15(20):24858\u201367.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3949_CR162","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.xphs.2019.06.015","volume":"109","author":"JR Snell","year":"2020","unstructured":"Snell JR, Monticello CR, Her C, Ross EL, Frazer-Abel AA, Carpenter JF, et al. DEHP nanodroplets leached from Polyvinyl chloride IV bags promote aggregation of IVIG and activate complement in human serum. J Pharm Sci. 2020;109(1):429\u201342.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3949_CR163","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00579710","volume":"18","author":"B Mass","year":"1996","unstructured":"Mass B, Huber C, Kr\u00e4mer I. Plasticizer extraction of Taxol infusion solution from various infusion devices. Pharm World Sci. 1996;18(2):78\u201382.","journal-title":"Pharm World Sci"},{"issue":"1","key":"3949_CR164","first-page":"91","volume":"32","author":"AG Hall","year":"2006","unstructured":"Hall AG. Nurses: taking precautionary action on a pediatric environmental exposure: DEHP. Pediatr Nurs. 2006;32(1):91\u20133.","journal-title":"Pediatr Nurs"},{"key":"3949_CR165","unstructured":"FDA. Limiting the use of certain phthalates as excipients in CDER-regulated products. In: Guidance for Industry. 2012. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Limiting-the-Use-of-Certain-Phthalates-as-Excipients-in-CDER-Regulated-Products_pdf.pdf. Accessed 12 Sept 2024."},{"key":"3949_CR166","unstructured":"FDA. Bottled water quality standard: establishing an allowable level for di (2-ethylhexyl) phthalate small entity compliance guide. In: Guidance for Industry. 2012. Available from: https:\/\/www.fda.gov\/media\/84475\/download. Accessed 12 Sept 2024."},{"issue":"6","key":"3949_CR167","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1002\/jps.22045","volume":"99","author":"HC Mahler","year":"2010","unstructured":"Mahler HC, Huber F, Kishore RS, Reindl J, R\u00fcckert P, M\u00fcller R. Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters. J Pharm Sci. 2010;99(6):2620\u20137.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3949_CR168","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.memsci.2008.08.046","volume":"325","author":"JX Zhou","year":"2008","unstructured":"Zhou JX, Qiu J, Jiang G, Zhou C, Bingham N, Yeung H, et al. Non-specific binding and saturation of Polysorbate-20 with aseptic filter membranes for drug substance and drug product during mAb production. J Membr Sci. 2008;325(2):735\u201341.","journal-title":"J Membr Sci"},{"key":"3949_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108711","volume":"112","author":"C Ogawa","year":"2019","unstructured":"Ogawa C, Inoue M, Yatabe M, Nagayama Y, Gomi H, Nakadate K, et al. Analysis of inline-filter blockage with trastuzumab formulation using scanning-electron microscopy. Biomed Pharmacother. 2019;112:108711.","journal-title":"Biomed Pharmacother"},{"key":"3949_CR170","unstructured":"Baxter. Compatible Baxter IV Sets. Available from: https:\/\/ushospitalproducts.baxter.com\/sites\/g\/files\/ebysai2186\/files\/2023-10\/DOC_11182_Rev_AC.pdf. Accessed 18 Oct 2024."},{"key":"3949_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104277","volume":"196","author":"C Duggan","year":"2024","unstructured":"Duggan C, Hernon O, Dunne R, McInerney V, Walsh SR, Lowery A, et al. Vascular access device type for systemic anti-cancer therapies in cancer patients: a scoping review. Crit Rev Oncol Hematol. 2024;196:104277.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3949_CR172","unstructured":"Kolikof J, Peterson K, Williams C, Baker AM. Central venous catheter insertion. 2025. StatPearls Publishing LLC. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32491730. Accessed 21 Oct 2024."},{"key":"3949_CR173","unstructured":"Vygon. Antimicrobial multi-lumen CVC STAR multistar 3 UP; 2024. Available from: https:\/\/www.vygon.com\/en\/products\/vascular\/adult-central-venous-catheters-cvc\/antimicrobial-multi-lumen-cvc-star\/multistar-3. Accessed 21 Oct 2024."},{"key":"3949_CR174","unstructured":"Vygon. Leadercath expert; 2024. Available from: https:\/\/www.vygon.com\/en\/products\/vascular\/adult-central-venous-catheters-cvc\/antimicrobial-single-lumen-cvc-expert\/leadercath-expert. Accessed 21 Oct 2024."},{"key":"3949_CR175","unstructured":"Vygon. High Flow CVC Multicath 3 HF UP; 2024. Available from: https:\/\/www.vygon.com\/en\/products\/vascular\/adult-central-venous-catheters-cvc\/high-flow-cvc\/multicath-3-hf. Accessed 21 Oct 2024."},{"key":"3949_CR176","unstructured":"Vygon. Hybrid implantable ports polysite surgical; 2024. Available from: https:\/\/www.vygon.com\/en\/products\/vascular\/implantable-ports\/hybrid-implantable-ports\/polysite-surgical. Accessed 21 Oct 2024."},{"key":"3949_CR177","unstructured":"Braun B. Certofix central venous catheter sets; 2024. Available from: https:\/\/catalogs.bbraun.com\/en-01\/p\/PRID00000569\/certofix-duo-hf?bomUsage=documents. Accessed 21 Oct 2024."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03949-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:07:11Z","timestamp":1779358031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03949-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":177,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03949-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}